Research News
View articles by month and year
-
Very Early Study Suggests Herceptin May Help Treat Some HER2-Negative Breast Cancers
A very early study done in mice suggests that Herceptin may effectively treat very small breast cancer tumors in bones, even though the original cancer was classified as HER2-negative.
-
T-DM1 (Kadcyla) Wins FDA Approval
Kadcyla, a targeted therapy medicine, has been approved by the U.S. Food and Drug Administration to treat HER2-positive metastatic breast cancer that has previously been treated with Herceptin and a taxane chemotherapy.
-
Heart Problems Happen More Often Than Thought in Older Women After Herceptin Treatment
A large study has found that older women diagnosed with early-stage, HER2-positive breast cancer treated with Herceptin have a higher risk of heart failure than women who didn’t get Herceptin.
-
One Year of Herceptin Best for Reducing Recurrence Risk of Early-Stage HER2-Positive Disease
Results from two studies confirm that 1 year of Herceptin, rather than 2 years or 6 months, after surgery seems to be best for reducing recurrence risk in women diagnosed with HER2-positive early-stage breast cancer.
-
Injectable Herceptin Shows Promise
A study suggests that an injectable form of Herceptin works just as well as and is as safe as the standard IV form of Herceptin to treat HER2-positive, early-stage breast cancer before surgery.
-
Perjeta Improves Overall Survival in HER2-Positive, Metastatic Disease
More results from the CLEOPATRA study show that women who got Perjeta, Herceptin, and Taxotere had better overall survival than women who got only Herceptin and Taxotere.
-
FDA Approves Perjeta for Metastatic, HER2-Positive Disease
The FDA has approved using Perjeta (chemical name: pertuzumab) in combination with Herceptin and Taxotere to treat HER2-positive, metastatic breast cancer that hasn't been treated with either Herceptin or chemotherapy yet.
-
T-DM1 Works Better on Advanced-Stage, HER2-Positive Cancer Than Standard Meds
A study found that women diagnosed with advanced-stage, HER2-positive breast cancer that had stopped responding to a standard regimen lived longer without the cancer growing when they got the experimental medicine T-DM1 compared to women who got a different regimen.
-
Large Review Study Confirms Herceptin’s Benefits
A large review study has found that women diagnosed with HER2-positive breast cancer and treated with Herceptin were less likely to have the cancer come back and more likely to survive compared to women who didn't get Herceptin.
-
Studies Evaluate Treatments Before Surgery for HER2-Positive Disease
Research suggests that using both Herceptin and Tykerb with Taxol before surgery to treat early-stage or locally advanced HER2-positive breast cancer is better than either alone with Taxol; if only one is given before surgery, Herceptin offers more benefits than Tykerb.
